With Phase III data in lung cancer on the horizon, SR Pharma plc has decided that it was pushing the manufacturing envelope with its SRL 172 heat killed suspension of Mycobacterium vaccae.

SR Pharma (LSE:SPA, London, U.K.) last week announced that it has reformulated SRL172 to treat asthma, which trails the company's cancer program in the clinic, to overcome manufacturing volume limitations it could foresee developing as clinical demands from both programs continued to grow.